Strategic partnership Chiesi Group’s planned acquisition and the 2025 leadership appointments signal strategic shifts and potential collaboration opportunities across commercialization, market access, and patient support programs for HAE therapies.

Global expansion KalVista’s international footprint with global teams and partnerships, including Multicarepharma, highlights opportunities to co-develop or co-commercialize in emerging markets and expand patient reach for EKTERLY and other protease inhibitors.

Pediatric growth Positive Phase 3 data for EKTERLY in children 2-11 suggests demand for pediatric labeling and dosing support, enabling partnerships in pediatric clinical development, patient access programs, and payer strategies.

Commercial leadership executive changes such as the CCO transition to the board and newly appointed COO indicate evolving commercialization strategies, creating openings for BD alliances, market access collaborations, and salesforce augmentation.

Strategic funding Significant funding depth and a large revenue range position KalVista for strategic collaborations, licensing deals or co-development financings with partners seeking access to novel oral protease inhibitors and HAE-focused therapies.